Overview

Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China.

With years of life sciences expertise and local knowledge, GIBF serves as an invaluable strategic investor and partner in China for conducting multi-center clinical trials, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.

Our Strategy

Enabling value creation by investing in Chinese subsidiaries of foreign companies active in the biomedical outside China


GIBF partners with select companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to manage the new enterprises as the majority shareholders.

Portfolio

Companies Overview

Partnering with top-tier international life sciences companies offering innovative solutions to Chinese healthcare needs.

Company

Kamari Pharma

Sector

Pharma

Company

Corneat Vision

Sector

Medical Device

Company

Silenseed

Sector

Pharma
Our People

Meet Our Management

Where global leaders in life sciences meet local talent to achieve cross-border investments and companies formation.

PROFESSOR SHLOMO NOY

Chief Medical Officer

CARL GENG

Managing Director

Latest News

Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
Kamari Pharma announced the completion of an $8 million investment by the Chinese fund...
GIBF (China-Israel) Fund Raised 300 million Dollars on the Second Fund
The fund, co-owned by Dr. Shuki Gleitman, Prof. Shlomo Noy and Avner Lushi, also...
Opening Ceremony of Guangzhou Sino-Israel Bio Incubation Center
The fund, co-owned by Dr. Shuki Gleitman, Prof. Shlomo Noy and Avner Lushi, also...